4basebio (AIM:4BB) has signed a non-exclusive Strategic Collaboration and Marketing Agreement with Genezen, a viral vector contract development and manufacturing organisation (CDMO) owned by Ampersand Capital Partners.
The AIM-listed company specialises in enzymatically produced, cell-free DNA for genetic medicines.
Under the deal, Genezen gains access to 4basebio's Research Use Only, High-Quality and GMP-grade hpDNA technology as starting material for drug developers' clinical programmes. The two companies will also collaborate on commercial activities, including joint sales and technical presentations to prospective customers.
4basebio's enzymatic manufacturing process removes microbial contamination and antibiotic resistance genes from the DNA production chain, which the company says can improve safety profiles and shorten development timelines from sequence design to clinical use.
Christine Wolosin, 4basebio's chief commercial officer, said the partnership reflects "our commitment to pairing our proprietary DNA technology with partners who share our dedication to safety, quality, and reliability."
Susan DeCosta, Genezen's chief technical and commercial officer, said the arrangement gives viral vector developers tools to "build more efficient, scalable manufacturing strategies from the outset."
News Intelligence what this means for the company
4basebio has signed a non-exclusive marketing and collaboration agreement with Genezen, a viral vector CDMO, to supply its enzymatically produced DNA platform as starting material for drug developers' clinical programmes. The deal includes joint sales and technical presentations but carries no disclosed financial terms, making its revenue impact impossible to assess.
- Genezen gains access to 4basebio's GMP-grade hpDNA technology, potentially expanding 4basebio's addressable market into viral vector manufacturing—a use case not previously detailed in available company information.
The agreement is non-exclusive and carries no disclosed economics, limiting visibility into whether this represents a meaningful revenue driver or primarily a distribution channel. The deal's classification as inside information suggests materiality under UK regulations, but without financial terms or exclusivity, the strategic value to 4basebio remains opaque.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
